#	Pagina
attuale pagina	/open-h2020/projects/217466/results.html

Report

Teaser, summary, work performed and final results

Periodic Reporting for period 1 - Stellar i-ris (First non-invasive, reliable and quickest biometric system detecting usersâ€™ fatigue and narcotics consumption for road safety and the prevention of accidents at safety-critical workplaces in Europe)

Teaser

Summary

Stellar i-ris aims to prevent and reduce accidents on roads and at safety-critical workplaces due to usersâ€™ tiredness and narcotics (incl. alcohol, drugs, psychoactive medicine) intake. In the past 10 years, 376,343 fatal road accidents were reported in the EU. These accidents cause even more injuries and cost at the global level 1-3% of the worldâ€™s GDP. Occupational accidents cause 350,000 deaths /year and millions of serious injuries worldwide. It is estimated that driversâ€™ tiredness and narcotics intake cause approx. 27% of fatal road accidents. This has dramatic effects on our economy, society, infrastructure and healthcare systems. Yet for time and cost reasons, road users and safety-critical professions are tested very rarely. Scientifics estimate a high â€œhiddenâ€ number of cases of tiredness and driving under the influence (DUI) of narcotics. This is due to the absence of reliable, all-in-one tests on the market. No tiredness detection system is currently used by traffic authorities. The pupillary light reflex - a recognised marker for tiredness and narcotics - is one of the most relevant indicators.
Current detection systems are not economically viable or present technical drawbacks (analysis time, accuracy, invasiveness, heavy equipment). Company Stellar offers worldwide the first non-invasive tiredness (proof of concept) and narcotics detection system using a unique process and algorithm for the biometric measurement of the human pupil light reflex, delivering reliable results immediately. It includes 2 product concepts: i-ris HEAD, closed measurement glasses with IR-retina illumination, targeted to controllers (traffic authorities, OHS specialists, employers) and i-ris APP, a self-detection smartphone application, targeted to end users (drivers, workers at safety-critical workplaces). The innovation targets the markets of drug-of-abuse and tiredness testing in Europe â€“ together estimated at â‚¬1 billion.
The goals of the Stellar i-ris innovation project are:
1) to offer for the first time a reliable and price/performance competitive product solution for the biometric measurement of the human pupil light reflex;
2) to enable our target users â€“ on the one side our so-called controllers â€“ to perform easy-of-use, quick and accurate prevention controls on a frequent up to a systematic basis (e.g. at workplace); and, on the other side, our end users to perform self-detection tests to protect themselves, others but also the surrounding infrastructures, environment and to a larger extent the society from accidents on roads and at work due to tiredness, or due to the intake of alcohol, drugs or the abuse of psychoactive medicines;
3) to add value to the European markets of drug-of-abuse and tiredness testing by introducing an until now unique solution for the detection of tiredness and narcotic consumption that will improve state-of-the-art prevention controls in terms of accuracy, speed of measurement and non-invasiveness;
4) to enable Stellar to gain a leading market position in providing measurement solutions based on pupillometry as drug-of-abuse and tiredness test products for road safety and occupational health and safety â€“ with an easy, simple and affordable solution that can be applied to all safety-critical sectors (i.a. air, road, rail, sea passenger and goods transport, as well as nuclear, oil and gas, chemical, construction and offshore (wind or oil) industries).

Work performed

The performed activities in the first project period included: the technical adaption for i-ris HEAD and i-ris APP (software and hardware), activities towards the system integration and validation in operational environment, the preparation for pre-series and small series production, as well as commercialisation and dissemination activities.
So far, the performed activities are within the current work plan schedule in terms of time and content.
Within the first project period, several commercialisation, communication and dissemination activities were successfully carried out. Numerous sales partnerships for commercialisation in Germany and further European countries have been acquired and set up, other promising negotiations are still under preparation.
The project management has provided for the efficient and successful performance of the project and has taken over all the important tasks such as project monitoring (schedule and budget), human resources management, management of administrative, contractual and legal aspects as well as communication with the EASME representatives.
The overall progress of the first project period has contributed to the overall objectives to a large extent. All originally set objectives have been met and, in some cases, exceeded.

Final results

Most unique selling points of the Stellar i-ris solution are: its non-invasiveness for users, its extremely high speed of measurement (within seconds), its high measurement accuracy, the small size of the system and equipment, its affordability, the considerable reduction of first test costs and of subsequent laboratory costs for controlling authorities, its user-friendliness, as well as the flexibility and robustness of the test setup and construction. Stellar expects a large impact for the Stellar i-ris technology and products, with a foreseen contribution to the company turnover of â‚¬30 million and 102 employees by 2023.